Raymond James Financial Inc. Purchases New Position in Glaukos Co. (NYSE:GKOS)

Raymond James Financial Inc. purchased a new stake in shares of Glaukos Co. (NYSE:GKOS) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 112,771 shares of the medical instruments supplier’s stock, valued at approximately $16,910,000. Raymond James Financial Inc. owned approximately 0.20% of Glaukos at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of GKOS. Wellington Management Group LLP grew its stake in Glaukos by 294.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock worth $284,501,000 after purchasing an additional 1,630,270 shares in the last quarter. State Street Corp grew its stake in Glaukos by 5.3% during the 3rd quarter. State Street Corp now owns 1,954,449 shares of the medical instruments supplier’s stock worth $254,626,000 after purchasing an additional 98,109 shares in the last quarter. Primecap Management Co. CA grew its stake in Glaukos by 2.0% during the 3rd quarter. Primecap Management Co. CA now owns 1,245,185 shares of the medical instruments supplier’s stock worth $162,223,000 after purchasing an additional 24,370 shares in the last quarter. Geode Capital Management LLC grew its stake in Glaukos by 6.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,172,016 shares of the medical instruments supplier’s stock worth $152,722,000 after purchasing an additional 66,134 shares in the last quarter. Finally, Loomis Sayles & Co. L P grew its stake in Glaukos by 21.6% during the 3rd quarter. Loomis Sayles & Co. L P now owns 673,751 shares of the medical instruments supplier’s stock worth $87,776,000 after purchasing an additional 119,527 shares in the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $103.12 on Tuesday. The business’s fifty day moving average price is $139.82 and its two-hundred day moving average price is $137.49. The stock has a market cap of $5.83 billion, a PE ratio of -35.93 and a beta of 0.99. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. Glaukos Co. has a one year low of $85.04 and a one year high of $163.71.

Glaukos (NYSE:GKOS) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. On average, analysts forecast that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GKOS has been the subject of several analyst reports. BTIG Research upped their price objective on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Needham & Company LLC upped their price objective on Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. UBS Group initiated coverage on Glaukos in a research report on Friday, December 6th. They set a “buy” rating and a $182.00 price objective for the company. Morgan Stanley cut Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research report on Monday, December 2nd. Finally, Mizuho raised Glaukos from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $163.25.

Insider Transactions at Glaukos

In other news, COO Joseph E. Gilliam sold 3,328 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at $15,310,024.65. This trade represents a 3.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gilbert H. Kliman sold 10,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $150.28, for a total value of $1,502,800.00. Following the sale, the director now owns 32,336 shares in the company, valued at $4,859,454.08. This trade represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,744 shares of company stock worth $2,504,131 over the last quarter. 6.40% of the stock is currently owned by insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.